Research ArticleNEURODEGENERATIVE DISORDERS

The brain penetrant PPARγ agonist leriglitazone restores multiple altered pathways in models of X-linked adrenoleukodystrophy

See allHide authors and affiliations

Science Translational Medicine  02 Jun 2021:
Vol. 13, Issue 596, eabc0555
DOI: 10.1126/scitranslmed.abc0555

Article Information

vol. 13 no. 596

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication April 3, 2020
  • Resubmitted August 6, 2020
  • Accepted for publication March 18, 2021
  • .

Author Information

  1. Laura Rodríguez-Pascau1,,
  2. Anna Vilalta1,,
  3. Marc Cerrada1,
  4. Estefania Traver1,
  5. Sonja Forss-Petter2,
  6. Isabelle Weinhofer2,
  7. Jan Bauer3,
  8. Stephan Kemp4,
  9. Guillem Pina1,
  10. Sílvia Pascual1,
  11. Uwe Meya1,
  12. Patricia L. Musolino5,
  13. Johannes Berger2,
  14. Marc Martinell1 and
  15. Pilar Pizcueta1,*
  1. 1Minoryx Therapeutics S.L., Barcelona 08302, Spain.
  2. 2Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Vienna 1090, Austria.
  3. 3Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Vienna 1090, Austria.
  4. 4Department of Clinical Chemistry and Pediatrics, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, Netherlands.
  5. 5Neurosciences Intensive Care Unit, Massachusetts General Hospital, Boston, MA 02114, USA.
  1. *Corresponding author. Email: ppizcueta{at}minoryx.com
  • These authors contributed equally to this work.

Altmetric

Article usage

Article usage: June 2021 to July 2021

AbstractFullPdf
Jun 20215166630394
Jul 202138910160

Stay Connected to Science Translational Medicine